Context Therapeutics grants 45,000 options to director

Context Therapeutics Inc. director Philip W. Kantoff reported a new stock option grant.

Rhea-AI Filing Summary

Context Therapeutics Inc. director Philip W. Kantoff reported a new stock option grant. He received options to buy 45,000 shares of common stock at an exercise price of $0.5760 per share, bringing his reported derivative holdings in this grant to 45,000 options.

The option vests and becomes exercisable on the earlier of June 24, 2027, the one-year anniversary of the grant date, or the company’s 2027 annual meeting of stockholders, subject to his continued service with the company. The options expire on June 23, 2036. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 1 txn

Insider Kantoff Philip W.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 45,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Key Figures

Option grant size: 45,000 options Exercise price: $0.5760 per share Post-grant derivative holdings in this award: 45,000 options +3 more

6 metrics

Option grant size 45,000 options Stock Option (right to buy) granted to director Philip W. Kantoff

Exercise price $0.5760 per share Conversion or exercise price of the stock options

Post-grant derivative holdings in this award 45,000 options Total shares underlying options following the transaction

Vesting date trigger June 24, 2027 Earlier of one-year anniversary or 2027 annual meeting, subject to service

Alternative vesting trigger 2027 annual meeting Vests on earlier of June 24, 2027 or 2027 annual meeting

Option expiration June 23, 2036 Expiration date of the stock options

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, vests and becomes exercisable, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vests and becomes exercisable financial

"The option vests and becomes exercisable on the earlier of"

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Context Therapeutics (CNTX) director Philip W. Kantoff report on this Form 4?

Philip W. Kantoff reported receiving a stock option grant for 45,000 shares of Context Therapeutics common stock. The options are a compensation-related award, not an open-market stock purchase or sale, and give him the right to buy shares at a fixed exercise price.

How many Context Therapeutics (CNTX) options did Philip W. Kantoff receive?

He received stock options covering 45,000 shares of Context Therapeutics common stock. These derivative securities give him the right to purchase shares in the future at a preset exercise price, subject to the vesting schedule and continued service conditions described in the filing footnote.

What is the exercise price of Philip W. Kantoff’s CNTX stock options?

The options have an exercise price of $0.5760 per share. This means Kantoff can buy Context Therapeutics common shares at $0.5760 once the options vest, provided he remains in service and exercises them before the June 23, 2036 expiration date.

When do Philip W. Kantoff’s Context Therapeutics options vest?

The options vest on the earlier of June 24, 2027 or Context Therapeutics’ 2027 annual meeting of stockholders. Vesting is also subject to Kantoff’s continued service with the company, so leaving before these dates could affect his ability to exercise the grant.

When do Philip W. Kantoff’s CNTX stock options expire?

The options expire on June 23, 2036, giving Kantoff a multi-year window to exercise after they vest. If he does not exercise by the expiration date, the right to buy Context Therapeutics shares at the $0.5760 exercise price will lapse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kantoff Philip W.

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915, UNIT #15

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.576	06/24/2026		A		45,000		(1)	06/23/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)